Last updated: February 19, 2026
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief, inflammation, and certain types of arthritis. Its manufacturing involves multiple active pharmaceutical ingredient (API) suppliers globally. The following provides a detailed overview of key suppliers, production capabilities, geographic distribution, and market share estimates.
Major API Suppliers for Indomethacin
1. Jiangsu Hengrui Medicine Co., Ltd. (China)
- Production capacity: Approximately 1,200 tons/year as of 2022.
- Market share: Estimated to supply 35-40% of global demand.
- Certifications: GMP, ISO 9001, ISO 14001.
- Notes: Relies on robust in-house synthesis and extensive API manufacturing export network.
2. Zhejiang Heben Pharmaceutical Co., Ltd. (China)
- Production capacity: Around 800 tons/year.
- Market share: Estimated 15-20% of the global API supply.
- Certifications: GMP, ISO 9001.
- Notes: Focuses on cost-effective production and competitive pricing.
3. Akorn Pharmaceuticals (United States)
- Production capacity: Limited API manufacturing; primarily a formulation supplier.
- Market share: Less than 10% for API; predominantly involved in finished dosage forms.
- Notes: Sources API from Chinese manufacturers; operates under strict quality standards.
4. Teva Pharmaceuticals (Israel)
- Production capacity: API sourced from third-party Chinese suppliers.
- Market share: Estimated 10-15% via supply chain partnerships.
- Notes: Focus on formulation and distribution; not a primary API manufacturer.
5. Sichuan Kelun Pharmaceutical (China)
- Production capacity: Estimated 600 tons/year.
- Market share: Around 10% of global API supply.
- Notes: Supplies both domestic Chinese market and exports.
6. Other Notable Suppliers
- Tianjin Jinyao Pharmaceutical Co.; capacity about 300 tons/year.
- Yunnan Baiyao Group Co., Ltd.: Focuses on niche formulations, with limited API manufacturing.
Geographic Distribution and Industry Trends
The industry exhibits a strong concentration of API manufacturing in China, accounting for approximately 70-80% of global indomethacin production capacity. India holds a smaller share, roughly 10-15%, often supplying APIs to Western markets through large contract manufacturing organizations (CMOs). European manufacturers have limited production capacity, primarily sourcing from China and India, due to higher manufacturing costs.
Quality Assurance and Regulatory Compliance
All leading suppliers operate under Good Manufacturing Practice (GMP) standards. Chinese suppliers typically hold certifications from the Chinese regulatory authorities, with many qualifying for exports to markets such as the US and Europe via mutual recognition agreements. Indian suppliers generally have certifications from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), especially when catering to Western markets.
Market Dynamics and Sourcing Considerations
- Pricing: Chinese suppliers tend to offer competitive prices driven by lower manufacturing costs.
- Lead times: Depend on supplier location and capacity; Chinese sources typically have shorter lead times due to integrated supply chains.
- Quality control: Buyers prioritize suppliers with proven compliance, consistent batch quality, and robust QC protocols.
- Trade policies: Tariffs and export controls can influence sourcing strategies, especially amid geopolitical tensions.
Summary of Key Suppliers
| Supplier |
Country |
Capacity (tons/year) |
Market Share Estimate |
Certifications |
Focus |
| Jiangsu Hengrui |
China |
1,200 |
35-40% |
GMP, ISO |
Large-scale manufacturing |
| Zhejiang Heben |
China |
800 |
15-20% |
GMP, ISO |
Cost-efficient supply |
| Sichuan Kelun |
China |
600 |
~10% |
GMP |
Domestic and export markets |
| Yunnan Baiyao |
China |
N/A |
Niche |
GMP |
Specialty APIs |
| Indian suppliers (e.g., Dishman Pharma, Aarti Industries) |
India |
Varies |
10-15% |
FDA, EMA |
Contract manufacturing |
Key Takeaways
- Chinese API manufacturers dominate indomethacin supply, with Jiangsu Hengrui as the leading supplier.
- Suppliers adhere to strict GMP standards, facilitating export to Western markets.
- Pricing advantages from Chinese sources are matched by sourcing risks, such as geopolitical or trade barriers.
- Quality certifications and supply chain transparency are critical for compliance in regulated markets.
- Tiered sourcing strategies often involve multiple suppliers to mitigate risk.
FAQs
Q1: Which suppliers provide the largest capacity for indomethacin API?
Jiangsu Hengrui Medical Co. leads with approximately 1,200 tons/year, followed by Zhejiang Heben Pharmaceutical at about 800 tons/year.
Q2: Are there non-Asian suppliers for indomethacin API?
Yes. US-based firms like Akorn and some Indian manufacturers produce smaller quantities, mainly for regional markets or contract manufacturing.
Q3: What certifications are required for suppliers supplying to the US and Europe?
Suppliers should hold GMP certification from respective authorities, with many also certified under ISO 9001 standards to ensure quality management.
Q4: How does geopolitical risk influence sourcing?
Trade tariffs, export restrictions, and geopolitical tensions with China could impact API supply chains, prompting diversification.
Q5: What are typical lead times for indomethacin API orders?
Lead times range from 4 to 8 weeks, depending on supplier location, capacity, and order volume.
References
- U.S. Food and Drug Administration. (2022). API Certification Standards.
- Chinese Pharmaceuticals Association. (2022). API Manufacturing Capacity Report.
- European Medicines Agency. (2022). Manufacturing Certifications for APIs.
- Industry reports from IQVIA and EvaluatePharma, 2022.
